Osteomark gets US clearance:
This article was originally published in Clinica
Executive Summary
Ostex' bone resorption test, Osteomark, has received US FDA clearance and the Seattle-based company expects sales to begin in the summer. Already available in Europe, Canada and Australia, Osteomark is based on technology developed by Dr David Eyre of the University of Washington. Ostex says it plans to enter into at least one additional worldwide partnership for marketing the assay: it already has collaborative deals with Merck & Co, Boehringer Mannheim and Mochida Pharmaceutical.